Thanks, Mike.

But the case for the new approach to screening for ovarian cancer is well documented in the NICE supporting evidence. For these difficult calls isn't it now necessary to do this on a basis of decision analysis and economic analysis?

I think that it's going to work well in practice. The bit I'm worried about is local variation in process and information management. To the best of my knowledge it won't have a programme management structure similar to that which is working well for screening for colorectal cancer.

Is anyone running local educational sessions on how to do this well?

Jonathan

On 19 Jul 2011, at 09:41, Colley, Michael wrote:

I don’t know who is the current LTOL guru but this is for attention of that brave soul.

In the light of recent NICE guidance the entry on CA-125 which reads

As CA 125 can be high in many normal or benign conditions (for example, pregnancy, menstruation, endometriosis, pelvic inflammatory disease) it is not useful as a screening test for cancer.

will (against one’s better judgement) need to be modified.

Michael

Dr. C . M. Colley
Consultant Chemical Pathologist
Great Western Hospital
Swindon SN3 6BB

------ACB discussion List Information-------- This is an open discussion list for the academic and clinical community working in clinical biochemistry. Please note, archived messages are public and can be viewed via the internet. Views expressed are those of the individual and they are responsible for all message content. ACB Web Site http://www.acb.org.uk Green Laboratories Work http://www.laboratorymedicine.nhs.uk List Archives http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html List Instructions (How to leave etc.) http://www.jiscmail.ac.uk/